RLMD
Relmada Therapeutics, Inc.NASDAQHealthcare$6.99-1.55%ClosedMarket Cap: $512.6M
As of 2026-04-06
Valuation
P/E (TTM)
—
PEG
—
P/B
5.44
P/S
0.00
EV/EBITDA
-8.50
DCF Value
$0.05
FCF Yield
0.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-170.8%
ROA
-61.0%
ROIC
-67.5%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $0.00 | NaN% | $-20.3M | $-19.9M | $-0.29 | — |
| FY 2025 | $0.00 | NaN% | $-59.1M | $-57.4M | $-1.45 | — |
| Q3 2025 | $0.00 | NaN% | $-10.3M | $-10.1M | $-0.30 | — |
| Q2 2025 | $0.00 | NaN% | $-10.2M | $-9.9M | $-0.30 | — |
| Q1 2025 | $0.00 | NaN% | $-18.2M | $-17.6M | $-0.58 | — |
| Q4 2024 | $0.00 | NaN% | $-19.1M | $-18.7M | $-0.62 | — |
| FY 2024 | $0.00 | NaN% | $-83.9M | $-80.0M | $-2.65 | — |
| Q3 2024 | $0.00 | NaN% | $-23.0M | $-21.7M | $-0.72 | — |
| Q2 2024 | $0.00 | NaN% | $-18.8M | $-17.8M | $-0.59 | — |
| Q1 2024 | $0.00 | NaN% | $-23.0M | $-21.8M | $-0.72 | — |
| Q4 2023 | $0.00 | NaN% | $-26.8M | $-25.2M | $-0.84 | — |
| FY 2023 | $0.00 | NaN% | $-103.7M | $-98.8M | $-3.28 | — |